Stockscreener 앱 받기
15.15
2.51%
-0.39
전일 마감가:
$15.54
열려 있는:
$15.56
하루 거래량:
82,435
Relative Volume:
0.06
시가총액:
$149.35M
수익:
$88.50M
순이익/손실:
$-35.27M
주가수익비율:
-4.5973
EPS:
-3.2954
순현금흐름:
$-23.70M
1주 성능:
-5.84%
1개월 성능:
+17.17%
6개월 성능:
+89.26%
1년 성능:
-5.89%
1일 변동 폭
$14.77
$16.02
1주일 범위
$14.50
$17.00
52주 변동 폭
$3.436
$20.21
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
15.15 | 153.20M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Is Biodesix (BDSX) stock outpacing its medical peers this year? - MSN
Wall Street analysts see an 86.45% upside in Biodesix (BDSX): Can the stock really move this high? - MSN
If You Invested $1,000 in BIODESIX INC (BDSX) - Stock Titan
Biodesix publishes lung nodule biomarker validation study By Investing.com - Investing.com Australia
Volatility Watch: Can Biodesix Inc expand into new marketsPrice Action & Weekly Momentum Stock Picks - baoquankhu1.vn
Biodesix, Inc.Common Stock (NQ: BDSX - The Chronicle-Journal
Biodesix publishes lung nodule biomarker validation study on 1,100 patients - Investing.com
Biodesix publishes lung nodule biomarker validation study - Investing.com
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis - The Manila Times
Biodesix Publishes Largest Lung Nodule Biomarker Study, Validating Nodify CDT® Test for Lung Cancer Risk Assessment - Quiver Quantitative
Biodesix Announces the Largest Lung Nodule Biomarker - GlobeNewswire
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Is Biodesix (BDSX) Shares Performing Better Than Other Medical Stocks This Year? - Bitget
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Yahoo Finance
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Biodesix (BDSX) Shares Surpassing Other Medical Stocks This Year? - Bitget
Treasury Yields: Can Biodesix Inc navigate macro headwinds2026 Pullbacks & Comprehensive Market Scan Insights - baoquankhu1.vn
Biodesix, Inc. (BDSX) reports Q4 loss, beats revenue estimates - MSN
Wall Street analysts think Biodesix (BDSX) could surge 111.62%: Read this before placing a bet - MSN
Decliners Report: Is Biodesix Inc benefiting from innovation trends2026 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Cannell & Spears LLC Sells 195,326 Shares of Biodesix, Inc. $BDSX - MarketBeat
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference - MarketBeat
Recap Report: What is the dividend yield of Biodesix IncNew Guidance & Accurate Trade Setup Notifications - baoquankhu1.vn
BDSX SEC FilingsBIODESIX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Biodesix Receives 'Moderate Buy' Rating from Analysts - National Today
Biodesix at Barclays Conference: Strategic Growth in Lung Cancer Diagnostics - Investing.com Canada
Biodesix Earnings Call Signals Growth With Caveats - TipRanks
Setup Watch: Is Biodesix Inc in a consolidation phase2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference - MarketBeat
What analysts say about Biodesix Inc stock2025 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target - Yahoo Finance
Wall Street experts predict that Biodesix (BDSX) may climb by 111.62%: Consider this information before making an investment decision - Bitget
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet - Finviz
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
BDSX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Monashee Investment Management Cuts Biodesix Stake by 95% - National Today
Canaccord reiterates Biodesix stock rating on strong Q4 results By Investing.com - Investing.com Canada
Canaccord reiterates Biodesix stock rating on strong Q4 results - Investing.com
Biodesix (BDSX) Q4 2025 Earnings Call Transcript - AOL.com
Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX - MarketBeat
Q4 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
William Blair Upgrades Biodesix (BDSX) - Nasdaq
William Blair Upgrades BDSX (Biodesix, Inc.) to Outperform Feb 2026 - Meyka
Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS - MarketBeat
William Blair Upgrades Biodesix (BDSX) to 'Outperform' | BDSX St - GuruFocus
Biodesix expects 2026 sales to crack $100M - BizWest
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
William Blair Upgrades Biodesix to Outperform From Market Perform - marketscreener.com
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
0.04%
자본화:
|
볼륨(24시간):